Unilife Corp

Unilife — Q4 FY2013 Earnings Presentation

7 slides from Unilife's earnings presentation, Sep 11, 2013

  1. Slide 1: Fiscal Year 2013 4th Quarter and Full Year Earnings Call

    Exhibit 99.2 Fiscal Year 2013th4Quarter and Full Year Earnings Call September 10, 2013 1

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Thispresentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management’s beliefs and assumptions and on information currently available to our manag

  3. Slide 3: Introductory Comments by Unilife CEO Alan Shortall

    Introductory Comments by Unilife CEO Alan Shortall Signing of commercial supply contract with Sanofi for use of Unifill Finesse with Lovenox Minimum purchase of 150MM units per year after four-year ramp program Preparing to finalize several additional contracts with other pharmaceutical companies re

  4. Slide 4: Lovenox Supply Contract Key Terms

    Lovenox®Supply Contract K – ey Terms Unilife Product Unifill Finesse (customized product from Unifill platform) Sanofi Drug Enoxaparin Sodium (Lovenox® / Clexane®) Drug Area Anti-thrombotics (low molecular weight heparin) Geographic Territory Global Contract Period Can extend up to 2024 Exclusivity

  5. Slide 5: Financial Data

    Financial Data 4Q 2013 4Q 2012 FY 2013 FY 2012 Revenues $ 0.7M $ 1.2M $ 2.7M $ 5.5M Research & development $ 6.5M $ 6.9M $ 21.7M $ 23.1M Selling, general & administrative $ 10.3M $ 7.1M $ 32.4M $ 27.7M Net loss $ 22.0M $ 14.9M $ 63.2M $ 52.3M Net loss per share d –iluted $ 0.25 $ 0.21 $ 0.78 $ 0.78

  6. Slide 6: A Deep Commercial Pipeline Driven by a Broad Product Portfolio

    A Deep Commercial Pipeline Driven by a Broad Product Portfolio Technology Platform Selection of Products Within Platform Prefilled Syringes Unifill® Unifill®Select For all prefilled biologics, drugs and vaccines EZMix™ EZMix™Select Reconstitution & Mixing For all liquid or dry drug combination thera

  7. Slide 7: Questions

    Questions uniuire™

Unilife — Q4 FY2013 Earnings Presentation on 6ix